Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.



In March 2011, ipilimumab (Yervoy; Bristol-Myers Squibb), a human monoclonal antibody specific for human cytotoxic T lymphocyte-associated antigen 4 (CTLA4), was approved by the US Food and Drug Administration (FDA) for the treatment of unresectable or metastatic melanoma.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: T cell activation.


  1. 1

    Jemal, A. et al. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277–300 (2010).

    Article  Google Scholar 

  2. 2

    Garbe, C. et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16, 5–24 (2011).

    CAS  Article  Google Scholar 

  3. 3

    Salama, A. K. & Hodi, F. S. Cytotoxic T-lymphocyte-associated antigen-4. Clin. Cancer Res. 5 Apr 2011 (doi: clincanres.2232.2011).

  4. 4

    Leach, D. R. et al. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).

    CAS  Article  Google Scholar 

  5. 5

    Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372–8377 (2003).

    CAS  Article  Google Scholar 

  6. 6

    US FDA. FDA labeling information — Yervoy. FDA website [online], (2011).

  7. 7

    Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. 8

    Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).

    CAS  Article  Google Scholar 

  9. 9

    Boni, A. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213–5219 (2010).

    CAS  Article  Google Scholar 

  10. 10

    Tong, M. et al. Wells Fargo Securities, equity research. (28 March 2011).

  11. 11

    Holfrod, J. et al. Jefferies company note, Bristol-Myers Squibb. (31 March 2011).

Download references

Author information



Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sondak, V., Smalley, K., Kudchadkar, R. et al. Ipilimumab. Nat Rev Drug Discov 10, 411–412 (2011).

Download citation

Further reading


Quick links